---
reference_id: "DOI:10.3389/fnins.2023.1287514"
title: "Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study"
authors:
- Sandra P. Smieszek
- Alyssa R. Kaden
- Caroline E. Johnson
- Jennifer L. Brzezynski
- Changfu Xiao
- Christos M. Polymeropoulos
- Gunther Birznieks
- Helene A. Emsellem
- Mihael H. Polymeropoulos
journal: Frontiers in Neuroscience
year: '2023'
doi: 10.3389/fnins.2023.1287514
content_type: abstract_only
---

# Case report: A patient with Delayed Sleep-Wake Phase Disorder and Optic Nerve Hypoplasia treated with tasimelteon: a case study
**Authors:** Sandra P. Smieszek, Alyssa R. Kaden, Caroline E. Johnson, Jennifer L. Brzezynski, Changfu Xiao, Christos M. Polymeropoulos, Gunther Birznieks, Helene A. Emsellem, Mihael H. Polymeropoulos
**Journal:** Frontiers in Neuroscience (2023)
**DOI:** [10.3389/fnins.2023.1287514](https://doi.org/10.3389/fnins.2023.1287514)

## Content

We present a case of an adult female diagnosed with Delayed Sleep-Wake Phase Disorder (DSWPD) and Optic Nerve Hypoplasia (ONH), with a confirmed delayed Dim Light Melatonin Onset (DLMO), who reports the inability to fall asleep at their desired bedtime and obtain adequate sleep nightly, despite the ability to have a full nightâ€™s sleep when not required to be up at a specific time for societal requirements. The participant was enrolled in an 11-month Open-Label Extension (OLE) following the randomized portion of a clinical study and was successfully treated with tasimelteon. DSWPD symptoms were resolved, and their previously delayed sleep-wake cycle was advanced.

Clinical trial registration

https://clinicaltrials.gov/ct2/show/NCT04652882
                      , identifier NCT04652882.